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Abstract: Leigh syndrome, also referred to as subacute necrotizing encephalomyelopathy, is a 
severe, early-onset neurodegenerative disorder that is relentlessly progressive and devastating to 
both the patient and the patient’s family. Attributed to the ultimate failure of the mitochondrial 
respiratory chain, once it starts, the disease often results in the regression of both mental and 
motor skills, leading to disability and rapid progression to death. It is a mitochondrial disorder 
with both phenotypic and genetic heterogeneity. The cause of death is most often respiratory 
failure, but there are a whole host of complications, including refractory seizures, that may 
further complicate morbidity and mortality. The symptoms may develop slowly or with rapid 
progression, usually associated with age of onset. Although the disease is usually diagnosed 
within the first year of life, it is important to note that recent studies reveal phenotypic het-
erogeneity, with some patients having evidence of in utero presentation and others having 
adult-onset symptoms.
Keywords: mitochondrial disorder, neurodegeneration, multisystemic disease, oxidative phos-
phorylation, mitochondrial DNA, neuroimaging, seizures
Introduction
Denis Leigh, a British neuropathologist, first described Leigh syndrome in 1951 in 
a postmortem pathologic evaluation of a 7-month-old infant who presented with 
severe encephalopathy and respiratory difficulties.1 However, it has only been during 
the last 15 years that the knowledge of the myriad of genetic mutations and natural 
histories of Leigh syndrome have significantly increased our understanding of this 
mitochondrial disorder. Leigh syndrome is relatively common, with an incidence of 
1 in 40,000 births, although certain populations have higher incidences. Because of 
two founder gene mutations found in two ethnic populations, one mitochondrial DNA 
(mtDNA)-encoded mutation leading to the disease occurs in 1 in 2,000 births in an 
isolated population near Quebec, Canada, and another nuclear-encoded mutation with 
an estimated homozygote frequency of 1:2,500 occurs in the Faroese population.2,3 
There is no known predilection for sex or race. The preschool incidence of Leigh 
syndrome was 1 in 32,000 in one population study within Northern Europe.4
The onset of symptoms is typically seen at between 3 and 12 months of age, but 
there is a wide range of disease onset. Onset can begin in utero with oligohydramnios 
and intrauterine growth restriction, but some cases do not become clinically observable 
until the second or third decade of life.5 When onset takes place during the first year, 
parental complaints of loss of head control and other motor milestones and floppiness 
prompt the initial medical investigation. Cognitive deterioration may appear   insidious The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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or may be rapid, usually after a bout of fever or onset of 
seizures. Nutritional troubles resulting from the decreased 
ability to feed may precede or exacerbate the underlying 
encephalopathy. Decreased body and head growth become 
apparent.
When the disease starts in the second or third year of life, 
the first complaints are usually difficulty in walking, dystonia, 
dysarthria, or intellectual regression. Patients are brought to 
medical attention most often for failure to thrive related to 
dysphagia and gastrointestinal distress. It is during this first 
examination that diffuse hypotonia is commonly noted. Later 
in the course, there are often complications with dystonic 
posturing not related to seizures, encephalopathy, and ataxia. 
These symptoms make it difficult to move purposefully and 
both interfere with proper motor development and result in 
significant delays and regressions. Decreased strength of 
respiratory muscles creates difficult-to-manage respiratory 
complications of illness. Initially intermittent, the respiratory 
symptoms ultimately become more consistent; hence the high 
incidence of death by respiratory failure.
Survival is variable, with most patients dying within a 
few years of diagnosis. In a large cohort of patients with 
Leigh syndrome, the median age of death was 2.4 years 
(range, 1 month–21 years).5 In this study, the survival prob-
ability was about 0.4 if a patient lived to 20 years of age, 
suggesting there is variability in survival. This likely is 
underscored by the genetic mutation type and the frequency 
of environmental stressors such as illness. Relapses with 
disease exacerbations are commonly a result of infections, 
usually with fever.5–7 Poor survival has been associated with 
age of disease onset, genetically identified disease, epileptic 
seizures, brainstem lesion on neuroimaging, failure to gain 
weight, and intensive care admission.5
Epilepsy is a common clinical finding that replicates 
overall disease clinical and genetic heterogeneity. In a recent 
review, seizures were seen in about 39% of patients with 
Leigh syndrome from all causes.5 In another large review 
focusing only on nuclear-encoded genes, a frequency of 
21% of Leigh syndrome patients were described as having 
seizures.7 Twenty-six percent of patients with pyruvate dehy-
drogenase (PDH) deficiency were noted to have seizures, but 
the review did not divide these patients into groups depend-
ing on whether they had Leigh syndrome or not, although 
only 27% of the total population had frank Leigh syndrome.8 
The phenotypic expression of seizures in Leigh syndrome 
represents a genetic heterogeneous population, with identical 
genetic mutations giving rise to seizures in some patients and 
not in others. Phenotypically, the same epilepsy   syndrome 
can be found in a variety of genetic mutations, both nuclear- 
and mtDNA-encoded.7,9 Seizure types range from infantile 
spasms to minor focal seizures.8–11 It has been our experience 
that up to 75% of Leigh syndrome patients with seizures 
remain medically intractable compared with other reports 
that suggest that only 30% are medically intractable (Saneto, 
unpublished data, 2014). In fact, the presence of seizures is 
a risk factor for early patient death and likely represents a 
more severe spectrum of cerebral involvement of the dis-
order.5 A complete understanding of this heterogeneity has 
not been attained.
Pathologically, Leigh syndrome is uniformly characterized 
by multifocal spongiform degeneration diffusely throughout 
the brain, including the basal ganglia, thalamus, cerebellum, 
brain stem, spinal cord, and optic nerves. Characteristic 
neuropathology includes spongiform lesions with relative 
preservation of neurons, associated with demyelination and 
gliosis.12 These lesions, often accompanied by demyelination, 
are seen bilaterally and symmetrically throughout the brain 
but have a particular predilection for the brainstem.13 Most 
of the symptoms seen on physical examination can be local-
ized to regions of the brain and brainstem that correspond to 
magnetic resonance imaging (MRI) changes. This correlated 
correspondence among neurological exam, MRI, and patho-
logical findings has been useful in replacing postmortem 
pathological analysis in diagnostic schemes.
Overall, the clinical picture of those afflicted by Leigh 
syndrome largely represents the areas of the brain involved, 
but there are characteristic, albeit variable, clinical manifes-
tations (Table 1). Because of the often involved brainstem, 
cerebellum, and basal ganglia in the majority of cases, the 
disease expresses itself not only with intermittent respira-
tory abnormalities but also with progressive oculomotor 
and other cranial nerve palsies, abnormal thermoregulation, 
ataxia, a variety of involuntary movements, and optic atrophy. 
Encephalopathy is manifested by motor delay, mental retar-
dation, progressive cognitive decline, seizures, and feeding 
difficulties.
Leigh syndrome: genetics
Leigh syndrome is an extremely genetically heterogeneous 
mitochondrial disorder. Newly identified nuclear genetic 
causes are increasing, largely as a result of the use of 
next-generation and whole-exome sequencing.14–16 Nuclear 
DNA mutations are inherited in a Mendelian fashion, with 
autosomal recessive and X-linked inheritance seen as the 
etiology of Leigh syndrome. Identification of causative 
mutations can be a cumbersome task, as the investigator The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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is confronted by two separate genomes, both nuclear and 
mitochondrial.17 The identification of pathological mutations 
in the mtDNA can be unclear due to mitochondrial genetics 
and physiology. As a result of multiple mtDNA molecules in 
individual mitochondrion, mutations can be heteroplasmic, 
meaning that mutated mtDNA and normal mtDNA coexist 
within individual mitochondrion. Identical DNA genomes, 
either normal or mutated, within the mitochondrion are 
called homoplasmic. Both situations can give rise to Leigh 
syndrome.18 However, the precise genetic cause of multiple 
cases of Leigh syndrome remains unknown.19
As of 2013, Leigh syndrome can be caused by mutations 
in more than 35 different genes (Table 2) of both nuclear 
and mitochondria origin, involving all five respiratory chain 
complexes.20 There are 13 mtDNA-encoded structural proteins 
of complex I, III, IV , and V , whereas the other approximately 77 
structural subunits are nuclear-encoded proteins. The electron 
donors of coenzyme Q10 and cytochrome c are also nuclear-
encoded proteins. Mutations in any of these structural com-
ponents of the respiratory chain can induce Leigh syndrome. 
Mutations in other genes involved in mitochondrial function, 
the tricarboxylic acid (TCA) cycle, and coenzyme Q10 have 
also been found as an etiology of Leigh syndrome.3,21–23 
Depending on the mutated genome, Leigh syndrome can be 
inherited as a maternally inherited mitochondrial trait (mtD-
NA-encoded), as an autosomal recessive trait resulting from 
mutations in nuclear genes encoding mitochondrial respiratory 
chain complex subunits, complex assembly proteins, coenzyme 
Q10, mitochondrial targeted tRNA synthetases synthetases, 
and X-linked genes involved in PDHA1 and complex I assem-
bly factor NDUFA1 (nuclear-encoded). Although most patients 
with Leigh syndrome have a mutation in nuclear DNA, about 
25% have a mutation in mtDNA.
Most pathological gene mutations are ultimately involved 
in the process of energy production in the mitochondria. 
Mitochondrial adenosine triphosphate (ATP) production is 
coupled to the oxidation of electron carriers nicotinamide 
adenine dinucleotide + hydrogen (NADH) and flavin adenine 
dinucleotide (FADH2).24 Five protein complexes make up the 
respiratory chain that are involved in oxidative phosphoryla-
tion (OXPHOS). Complex I, complex II, complex III, and 
complex IV make up the oxidative portion, and complex V 
makes up the phosphorylation segment of the mitochondrial 
respiratory chain. Complex V is also known as ATP synthase, 
as it uses the energy from the electrochemical proton gradi-
ent across the inner membrane produced by the reactions 
of complexes I–IV that reduce molecular oxygen to water. 
Complex V then uses this energy to catalyze the synthesis of 
ATP from adenosine diphosphate and inorganic phosphate.25 
NADH and FADH2, formed via the TCA cycle and fatty acid 
oxidation, respectively, are used as electron donors to reduce 
oxygen molecules. Mutations associated with the respiratory 
chain complexes either reduce or eliminate their activity, 
impairing mitochondrial energy production, which in turn ulti-
mately leads to cellular and organ dysfunction.26   Furthermore, 
the production of intracellular reactive oxygen species by 
both the mitochondria and the surrounding cells produces a 
proinflammatory environment that contributes to much of the 
tissue injury and organ impairment.27
Mitochondrial genetics imparts special inheritance 
patterns. Maternal inheritance imparts the disease mutation 
to all children of an affected woman. Multiple mtDNA per 
mitochondrion and multiple mitochondria per cell can lead 
to heteroplasmy, the combination of normal and abnormal 
mtDNA in the same cell. To date, most mitochondrial dis-
eases resulting from mtDNA are either a result of a high 
degree of heteroplasmy or homozygous mtDNA mutations.26 
Heteroplasmy creates one important characteristic feature 
of mtDNA-encoded disease: There is an association of the 
severity of the clinical manifestations of the disease with the 
extent to which mutant mtDNA exists in ratio to wild-type 
mtDNA in each cell. Intertissue variability likely occurs, and 
prospective studies could be considered and may help define 
organ specificity.
Nuclear-encoded mutations can be inherited in a Men-
delian fashion. Genes encoding the proteins involved in the 
structural components of the respiratory chain complexes, 
the electron carrier of coenzyme Q10, assembly proteins of 
the various complexes and super complexes, protein trans-
porters, and modifiers of mt tRNAs, can give rise to Leigh 
syndrome. Enzymes involved in the TCA cycle can also be 
involved in this syndrome. This wide range of components 
of mitochondrial pathophysiology produces a spectrum of 
disease.
Whether a result of nuclear- or mtDNA-encoded muta-
tion, ultimately it is impaired OXPHOS that leads to a 
critical nadir of cellular energy and subsequent cell death. 
The high-energy demand tissues are most vulnerable to this 
process and, in part, are responsible for the clinical features 
of Leigh syndrome. It is not surprising that although a wide 
range of clinical symptoms is found, most patients present 
similarly with neurological symptoms of brainstem and/or 
basal ganglia dysfunction, seizures, hypotonia, periodic dis-
ease exacerbation with illness, and progressive neurological 
decline. Four main groups of defects appear to be responsible 
for the vast majority of cases.The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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Table 1 Clinical manifestations seen with Leigh syndrome patients
Symptoms
Gastrointestinal
  Dysmotility
  Constipation
  Acid reflux
  vomiting
  Anorexia
  Dysphagia
  Failure to thrive (gain weight)
Pulmonary
  Abnormal respiration
  Hypoxia
Cardiac
  Hypertrophic cardiomyopathy
  Asymmetric septal hypertrophy
  ventricular septal defects
Neurologic
  Seizures
  Cognitive impairment
  Hypotonia
  Dystonia
  Neuropathy
  Generalized weakness
  Hyporeflexia
  Ataxia
  Chorea
  Spasticity
  Central apnea
  Stroke (metabolic)
  Tremor
Dermatologic
  Abnormal odor of skin
  Hyperpigmented skin eruptions
  Hypertrichosis
Metabolic/renal
  Lactic acidosis
  Tubulopathy
  Nephrotic syndrome
  Fanconi syndrome
endocrine
  Diabetes
  Thyroid dysfunction
Audiologic
  Sensorineural hearing loss
  Auditory neuropathy
immunologic
  impaired immunity
Ophthalmologic
  Nystagmus
  Ophthalmoparesis
  Retinitis pigmentosa
  Failure to acquire smooth pursuit
Musculoskeletal
  Muscle weakness
  Ptosis
  Pes cavus
PDH complex deficiency
Leigh syndrome can be caused by mutations in genes that 
serve to form the PDH complex (PDHC). Many patients 
with PDHC deficiency have Leigh syndrome with classic 
imaging findings. Biochemical defects can involve any of 
the three subunits of the enzyme complex of the activation 
of the complex by PDH phosphatase and can lead to lower 
PDH activity and the limitation of pyruvate entering the 
respiratory chain. This produces a severe reduction of the 
TCA cycle activity. Deficiencies of the X-linked E1n subunit 
of the PDHC, the most common etiology of Leigh syndrome, 
have been well-documented.8 Leigh syndrome has also been 
associated with the E3 component of PDHC, which, if disease 
is present, is autosomal recessively inherited. Patients with 
PDHC deficiency have an earlier onset, usually between 3 and 
6 months, with males usually having more severe disease. 
Females can also express the disease because of skewed 
X-inactivation.8 Interestingly, although more males died than 
females, females who had PDH deficiencies died earlier than 
the males.8 Clinical symptoms of PDHC deficiency can range 
from Leigh syndrome to intermediate ataxia or progressive 
neurodegenerative disorder. The reason for this range of 
phenotypes is not well understood.28
isolated respiratory chain complexes
Complex II is the smallest complex of the respiratory chain, 
and all four subunits (A, B, C, and D) are nuclear-encoded. 
Mutations in complex II are relatively rare, as are documented 
causes of mitochondrial disorders in general. Complex II 
is located on the inner membrane. It functions to oxidize 
FADH2 , transferring electrons to ubiquinone in the electron 
transport chain. These reactions are based on the functions of 
catalytic subunits A and B. More than ten different autosomal 
recessive pathogenic mutations in A have been described that 
cause mitochondrial disorders. Some patients described with 
complex II deficiency had the clinical phenotype and cerebral 
MRI findings consistent with Leigh syndrome, whereas oth-
ers had other findings and were not considered to have Leigh 
syndrome.29,30 The heterogeneity of disease expression is not 
completely understood.
Cytochrome oxidase deficiency
The most common cause of nuclear-encoded mutation 
Leigh syndrome is disruption of complex IV or cytochrome 
oxidase (COX). There are 13 subunits, three of which are 
encoded by mtDNA and the other 10 are nuclear encoded.31 
The assembly process of complex IV is not fully known, but The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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Table 2 Genes known to be associated with Leigh syndrome
Gene Defect Location Reference
BCS1L Complex iii Nuclear Morán et al, 201078
C12ORF65 Complex i Nuclear Antonicka et al, 201079
COX10 Complex iv Nuclear Böhm et al, 2006;32 Antonicka et al, 200331
COX11 Complex iv Nuclear Böhm et al, 200632
COX15 Complex iv Nuclear Böhm et al, 200632
FOXRED1 Complex i Nuclear Calvo et al, 201080
GFM1 Mitochondrial translation defect Nuclear Genetics Home Reference, 20112
LRPPRC Complex iv Nuclear Debray et al, 201137
MT-ATP6 Complex v Mitochondrial Saneto and Singh, 2010;6 Kucharczyk et al,  
2009;41 Baracca et al, 2007;39  
Santorelli et al, 19939
MT-ND1 Complex i Mitochondrial Lenaz et al, 200481
MT-ND2 Complex i Mitochondrial Genetics Home Reference, 20112
MT-ND3 Complex i Mitochondrial Leng et al, 2014;52 Gerards et al, 2013;20  
Levy et al, 201382
MT-ND4 Complex i Mitochondrial Mitchell et al, 200483
MT-ND5 Complex i Mitochondrial Kirby et al, 200384
MT-ND6 Complex i Mitochondrial Kirby et al, 200085
MT-TK Complex i Mitochondrial Rahman et al, 199612
MT-TL1 Complex i Mitochondrial Rahman et al, 199612
MT-TV Complex i Mitochondrial Rahman et al, 199612
MT-TW Complex i Mitochondrial Rahman et al, 199612
NDUFA1 Complex i X-linked Fernandez-Moreira et al, 200786
NDUFA2 Complex i Nuclear Hoefs et al, 200887
NDUFA4 Complex iv Nuclear Pitceathly et al, 201388
NDUFA9 Complex i Nuclear van den Bosch et al, 201288
NDUFA10 Complex i Nuclear Hoefs et al, 201190
NDUFA11 Complex i Nuclear Bénit et al, 200491
NDUFA12 Complex i Nuclear Ostergaard et al, 201091
NDUFAF2 Complex i Nuclear Hoefs et al, 200993
NDUFAF5 Complex i Nuclear Chol et al, 200310
NDUFAF6 Complex i Nuclear Genetics Home Reference, 20112
NDUFS1 Complex i Nuclear Bénit et al, 2001;94 Martín et al, 200593
NDUFS2 Complex i Nuclear Tuppen et al, 201096
NDUFS3 Complex i Nuclear Bénit et al, 200194
NDUFS4 Complex i Nuclear Quintana et al, 2010;97 Anderson et al,  
2008;98 Leshinsky-Silver et al, 200999
NDUFS7 Complex i Nuclear Lebon et al, 2007100,101
NDUFS8 Complex i Nuclear Marina et al, 2013102
NDUFV1 Complex i Nuclear Bénit et al, 200194
PDHA1 Pyruvate dehydrogenase deficiency X-linked Lissens et al, 2000;103 Rahman et al, 199612
PDHB Pyruvate dehydrogenase deficiency X-linked Quintana et al, 2009104
PDHX Pyruvate dehydrogenase deficiency X-linked Schiff et al, 2006105
PDSS2 Ubiquinone deficiency Nuclear López et al, 200621
PET100 Complex iv Nuclear Lim et al, 2014106
SCO2 Complex iv Nuclear Joost et al, 2010107
SDHA Complex ii Nuclear Pagnamenta et al, 2006108
SDHAF1 Complex ii Nuclear Ohlenbusch et al, 2012109
SLC19A3 Thiamine transport defect Nuclear Gerards et al, 201320
SUCLA2 Mitochondrial DNA depletion Nuclear Carrozzo et al, 2007;3 Ostergaard et al, 2007110
SUCLG1 Mitochondrial DNA depletion Nuclear Ostergaard et al, 201092
SURF1 Complex iv Nuclear Rossi et al, 200334
TACO1 Complex iv Nuclear weraarpachai et al, 2009111
TTC19 Complex iii Nuclear Atwal, 2013112
UQCRQ Complex iii Nuclear Barel et al, 2008113
Note: References listed are only a sample of published literature.The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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mutations in these genes, and in particular SURF1, also can 
produce Leigh syndrome.32 This complex is involved in the 
last step of electron transfer in the oxidative process of ATP 
production. Mutations leading to the disruption of complex 
IV are the most common cause of Leigh syndrome in the 
United Kingdom.33 These patients have a slightly later age 
of onset than those with PDHC deficiency, usually between 
8 and 12 months.
The most frequently mutated gene in COX-deficient Leigh 
syndrome is the nuclear-encoded SURF1 gene, located on 
chromosome 9q34 and important in the assembly and main-
tenance of COX activity. Eighty-three different mutations 
have been reported in 57 patients with approximately 80% 
truncating mutations.32 Truncating mutations in the SURF1 
gene are subsequently degraded, resulting in the absence of 
functional SURF1 protein. The loss of this protein reduces 
the formation of normal COX complexes, which impairs 
mitochondrial energy production. Most patients with SURF1 
mutations affecting COX have MRI abnormalities involv-
ing brainstem and subthalamic nuclei.34,35 However, there 
are some exceptions.36 The reasons for this heterogeneity in 
neuroimaging while retaining a homogeneous phenotypic 
presentation in Leigh syndrome are not well understood.
A particular unique subset of COX-deficient Leigh 
syndrome is French-Canadian Leigh disease (Saguenay-
Lac-St-Jean cytochrome c oxidase deficiency [LRPPRC]). 
LRPPRC is clinically distinct, with acute fatal acidotic crises 
on a backdrop of chronic moderate developmental delay and 
hyperlactatemia. The Leigh syndrome of LRPPRC differs 
from that of SURF1-related COX deficiency. LRPPRC has a 
different spectrum of associated abnormalities, with acidotic 
crises being particularly suggestive of LRPPRC-related Leigh 
syndrome. LRPPRC encodes leucine-rich pentatricopeptide 
repeat-containing protein, which may regulate the stability 
and handling of mature mitochondrial mRNA. Even among 
p. A354V homozygotes, pronounced differences in survival 
and severity occur, showing that other genetic and/or envi-
ronmental factors can influence outcome.37 It is unclear why 
the regulation of mRNA stability and handling alters COX 
activity more than the other respiratory chain complexes.
Mitochondrial ATPase 6 gene
Mutations of this gene result in the most common maternally 
inherited Leigh syndrome (MILS), the most widespread 
mtDNA mutation in Leigh syndrome. ATP 6 is part of 
complex V that alters the function of the proton channel 
and results in a loss of ATP-synthetic activity.38 When indi-
viduals have more than 90% heteroplasmy of mtDNA in 
their cells, they are classified as having MILS, and a rapidly 
  progressive course is characterized by bilateral subacute 
lesions of the basal   ganglia, which may extend to the brain-
stem, leading to the death of the patient.39 The ATP synthase 
enzyme is a multisubunit complex with a molecular mass of 
  approximately 550,000 Da. It has both a hydrophobic domain 
and a hydrophilic ATPase. ATP synthase defects may be of 
either mitochondrial or nuclear genetic origin, as the bio-
genesis of the mitochondrial ATP synthase has 14 subunits 
that are nuclear-encoded in addition to two mtDNA-encoded 
proteins.40,41
A nucleotide change (T.G and T.C) at the same loca-
tion in the mtDNA, 8993, affecting the ATP 6 subunit of 
the ATPase is also associated with neuropathy, ataxia, and 
retinitis pigmentosa (NARP), as well as MILS. Whereas 
MILS occurs when mutation load is greater than 90%, NARP 
is seen with percentages around 50%–60%.42 This difference 
in heteroplasmic load is a prime example of mitochondrial 
genetics, with low heteroplasmy versus a higher ratio of 
heteroplasmy causing different phenotypes.43 In 2007, 
Baracca et al tried to explain the difference in pathogenicity 
of these two diseases resulting from mutations of the same 
position of the ATP 6 gene of mtDNA and concluded that 
reactive oxygen species overproduction is likely a major 
pathogenic mechanism contributing to NARP versus MILS 
phenotypes.39
The degree of heteroplasmy producing NARP versus 
Leigh syndrome and producing varying levels of reactive 
oxygen species and degree of ATP production are likely 
not the full answer to phenotype. For example, a family at 
our institution demonstrated this continuum: A 45-year-
old man presented with intellectual impairment, retinitis 
pigmentosa, cerebellar ataxia, peripheral neuropathy, pes 
cavus with foot drop, and a negative family history. MRI 
revealed cerebellar atrophy. He was ultimately diagnosed 
with NARP after targeted mutation analysis revealed more 
than a 95% of mtDNA with m.8993 T.C mutation. The 
percentage of heteroplasmy should have produced the Leigh 
syndrome phenotype. A pedigree traced to the maternal 
grandmother and subsequent testing demonstrated 50% of 
mtDNA with 8993 mutation in the maternal grandmother, 
who had a daughter, the patient’s mother, with 66% and a 
son, the patient’s uncle, with 80%. The grandmother and 
mother were clinically normal, but the uncle was affected. 
The patient also had a deceased brother with more than 
95% of mtDNA with m.8993 T.C mutation. These data 
suggest that degree of ATP production via ATPase activity 
and amount of oxygen radical species produced cannot be The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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the total etiology of the phenotypic requirement of Leigh 
syndrome versus NARP. Interestingly, retinitis pigmentosa 
is a major sign that is not found in Leigh syndrome as a 
result of nuclear-encoded mutations.   Furthermore, there 
are no ragged red fibers. Five percent to 10% of Leigh 
syndrome cases have been attributed to mutations in the 
MT-ATP6 gene.
With the NARP m.8993 T.G mutation, it is possible 
to have NARP in one generation but then Leigh syndrome, 
NARP, and/or no clinical symptoms in another generation. 
This is an example of random segregation and “bottleneck 
effects” during oocyte development. MtDNA mutations are 
randomly segregated to the forming oocytes during postfer-
tilization of the female fetus.44,45 Heteroplasmy and type of 
missense mutation in m. 8993 play an important role in age 
of disease onset. Leigh syndrome has infantile onset, whereas 
NARP usually has childhood or adult onset.   Mitochondrial 
genetics and the degree of ATP production and oxidative 
reactive species as well as other undefined etiologies likely 
differentiate between onset and type of disorder. Interestingly, 
no other mutation in the mtDNA genome gives rise to NARP, 
although the reasons for this are not clear. A clear description 
of reproducible intertissue variability of mutation also has 
never been described.
Complex I deficiency
Abnormal respiratory chain enzyme activity is commonly 
found within complex I (NADH:ubiquinone oxidoreductase). 
It is the first and largest enzyme complex of the mitochondrial 
respiratory chain and OXPHOS system and plays critical 
roles in transferring electrons from NADH to ubiquinone 
and redox-driven proton translocation to maintain the elec-
trochemical gradient across the inner mitochondrial mem-
brane.46 It consists of 45 subunits: seven subunits are encoded 
by mtDNA, and 38 subunits are from nuclear DNA. In addi-
tion, there are multiple assembly proteins involved in func-
tional holoenzyme activity. There are at least ten assembly 
proteins that are of nuclear DNA origin that have associated 
disease.47 However, there are many more punitive candidate 
assembly factor genes involved in complex I assembly, 
suggesting that more nuclear-encoded genes remain to be 
discovered.7,47 Leigh syndrome can result from mtDNA and 
nuclear-encoded gene mutations associated with isolated 
complex I defects. In one large review study, 84% of patients 
with complex I dysfunction had complex I enzymatic activity 
changes as a result of nuclear-encoded mutations.7
Deficiency of complex I is the most commonly identi-
fied defect in childhood-onset mitochondrial disease and 
accounts for approximately a third of all cases of OXPHOS 
disorders.48 There are seven mtDNA-encoded subunits of 
complex I that are part of the highly conserved core of 
complex I. However, age of onset may differ by whether 
mtDNA- or nuclear-encoded defects are the etiology. Leigh 
syndrome induced by mtDNA-encoded gene mutations at 
age of onset may be related to a specific mutation. In three 
large cohort studies (n=188) of neonatal-onset mitochon-
drial disease, only three neonates had Leigh syndrome, 
and all three had the condition as a result of m.8993 T.G 
mutation.49–51 However, in infants and children, all of the 
mtDNA-encoded subunits of complex I (ND1, ND2, ND3, 
ND4, ND4l, ND5, and ND6) have been associated with 
Leigh syndrome.26,52–54 There have been at least 26 distinct 
mtDNA-encoded mutations giving rise to Leigh syndrome.55 
Phenotypical expressions may vary, with some patients with 
identical mtDNA-encoded mutations having either Leigh 
syndrome or another type of nonsyndromic mitochondrial 
disease. Heteroplasmy plays a role in phenotypic variation, 
but there must be other reasons for this variation in the 
phenotype, as similar percentages of heteroplasmy can give 
rise to distinct phenotypes.
There are 38 nuclear-encoded complex I subunits, of 
which seven form the highly conserved core subunits, 
NDUFS1–NDUFS3, NDUFS7, NDUFS8, and NDUFV1 and 
NDUFV2.56 Leigh syndrome has been described in each of 
these proteins.55 Associated subunits of complex I, NDUFS4, 
NDUFS7, and NDUFS8 and NDUFA1, NDUFA2, NDUFA9, 
and NDUFA10, have been linked to Leigh syndrome.7,57,58 
Assembly proteins have also been described, includ-
ing   NDUFAF1, NDUFAF4, ACAD9, NUBPL, C20orf7, 
C8orf38, and FOXRED1.7 As more refinements in gene 
discovery methodology occur, it is likely that more nuclear-
encoded complex I proteins will be found.
Leigh syndrome patients with complex I deficiency 
typically have normal early development but present in 
late infancy or early childhood with progressive neuro-
logical abnormalities consistent with Leigh syndrome. 
Presentation before 6 months usually includes symptoms 
of hypotonia, feeding problems, vomiting, encephalopa-
thy, epilepsy, and eye movement disturbances, whereas 
after 6 months, presentation was psychomotor retardation, 
pyramidal signs and symptoms, dystonia, ataxia, epilepsy, 
failure to thrive, vomiting, and optic atrophy.7 Stepwise 
neurodevelopmental regression may follow intercurrent 
illnesses. Although there may be some recovery noted, 
usually the child never returns to baseline before the illness. 
Nuclear-encoded complex I deficiency was associated with The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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brainstem involvement, optic atrophy, and basal ganglia 
involvement on MRI scans.7
Other mutations
Various mutations in mtDNA-encoded tRNA genes have 
been described as causing Leigh syndrome. Mutations 
include those in m.8344 A.G tRNA Lys, m.1644 G.T 
tRNA Val, m.3537 Tins, m.3243 A.G tRNA Leu, m.10410 
T.A tRNA Arg, and m.5523 T.G tRNA Trp.59–64 Other 
mtDNA-encoded mutations have been described in ribo-
somal proteins, such as m.896 A.G 12S rRNA and m.270 
A.G 16S rRNA.63
There are other nuclear-encoded genes involved in Leigh 
syndrome, although they are relatively uncommon. In their 
study, Gerards et al found a homozygous nonsense mutation 
in the thiamine transporter gene SLC19A3 (c.20 C.A).20 
This mutation resulted in a premature stop codon and, sub-
sequently, decreased thiamine uptake by components of the 
respiratory complex of the mitochondria. The phenotype was 
consistent with known clinical presentations and the disease 
course of Leigh syndrome.20
Carrozzo et al characterized a group of patients with 
SUCLA2 gene mutations in whom clinical presentation 
and MRI findings were consistent with Leigh syndrome.3 
There were many patients from the Faroe Islands having 
a common ancestor, suggesting a founder effect for this 
mutation. Presenting signs and symptoms included early-
  onset hypotonia, psychomotor delay and regression, pro-
gressive dystonic/athetoid movements, and sensorineural   
deafness. The SUCLA2 gene encodes the beta-subunit of the 
adenosine diphosphate-forming succinyl-CoA synthetase, 
a mitochondrial matrix enzyme that catalyzes the revers-
ible synthesis of succinyl-CoA from succinate and CoA. 
The reverse reaction occurs in the TCA cycle, whereas the 
forward reaction may produce succinyl-CoA for the activa-
tion of ketone and heme synthesis. Methylmalonic aciduria 
results from buildup of succinyl CoA and increased conver-
sion to methylmalonyl CoA. It is not entirely clear how a 
mutation in the SUCLA2 gene causes mtDNA dysfunction. 
Elpeleg et al theorized an interaction between succinyl-
CoA synthetase and nucleoside diphosphate kinase, both of 
which are crucial for the maintenance of ribonucleotides, 
and deoxyribonucleotides.22 Indeed, mtDNA depletion has 
been found in some patients.22
Coenzyme Q10 is a lipophilic molecule that functions 
as an electron carrier involved in the transfer of electrons 
from complex I and complex II to complex III, as well as a 
potent antioxidant. Recently, patients with mutations in the 
synthetic pathway of coenzyme Q10 synthesis, decaprenyl 
diphosphate synthase subunit 2, have a multisystem disorder 
that includes Leigh syndrome signs and symptoms together 
with nephrotic syndrome and focal seizures.21,23
Diagnosis
In view of the inconsistent nature of the disease and the 
notable absence of a specific biochemical or molecular 
defect,65 definitive diagnoses has relied on demonstration of 
the typical pattern of brain lesions on MRI or autopsy and 
clinical findings.12 Although affected areas appear hypodense 
as a result of tissue necrosis, on computed tomography scan, 
this test is much less reliable. Primary striatal involvement on 
MRI can suggest Leigh syndrome. However, neuroimaging 
findings can also vary depending on the particular genetic 
and/or biochemical defect. Other mitochondrial conditions 
such as PDH deficiency and complex V deficiency without 
Leigh syndrome, as well as nonmitochondrial diseases such 
as carbon monoxide intoxication, infantile bilateral striatal 
necrosis, Wilson disease, and juvenile Huntington’s chorea, 
can demonstrate basal ganglia changes. Biochemical find-
ings, clinical history, and physical examination can usually 
distinguish these disorders from Leigh syndrome. White mat-
ter lesions in the cerebral hemispheres may be so prominent 
as to mimic a leukodystrophy. Therefore, to be reasonably 
certain of the diagnosis of Leigh syndrome, strict criteria 
have been proposed on the basis of the combination of typical 
MRI findings (Figures 1 and 2), biochemical abnormalities 
such as the demonstration of a increased level of lactate in 
the cerebrospinal fluid, and a clinical picture that is consistent 
with the disease.12
Other neuroimaging findings can provide clues to the 
diagnosis. Diffusion characteristics and proton magnetic 
resonance spectroscopy (MRS) characteristics vary depend-
ing on the acuity of the lesion (Figures 1 and 2).66 In the 
acute phase of injury, when mitochondrial function is acutely 
impaired and ATP production is reduced, water motion will 
be reduced; this is seen as a hyperintense signal on diffusion 
weighted image acquisition. If no permanent damage ensues, 
diffusion may return to normal tissue intensity. However, 
if significant astroglial response or necrosis ensues in the 
injured area seen as hypointensity, diffusion or hyperintensity 
will be increased in the surrounding tissue. MRS has shown 
a decreased N-acetylaspartate peak and an elevated lactate 
peak, with lactate elevation most pronounced in areas with 
acute mitochondrial dysfunction (with consequent anaero-
bic glycolysis). The decrease in N-acetylaspartate suggests 
neuronal and/or axonal loss, evolving necrosis resulting from The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
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Figure 1 Axial MRi scan (A) and  MRS spectrum (B) of a 9-year old boy with Leigh 
syndrome due to a mutation in the mtDNA.
Notes: (A) Axial fluid-attenuated inversion recovery image from a 3 T scanner 
(Siemens  Trio) of a 9-year-old boy with Leigh syndrome resulting from a mitochondrial 
DNA mutation (m.11487 C.T). There is T2/fluid-attenuated inversion recovery 
hyperintensity in the bilateral caudate and putamen. ex vacuo dilation of the frontal 
horns and bodies of the lateral ventricles is well visualized. (B) Summed spectrum 
from central gray nuclei in the same patient using the point-resolved spectroscopy 
pulse sequence (3 T Siemens Trio; time to echo (Te), 288 ms; time to relaxation 
(TR), 1,700 ms; 16×16 acquisition, interpolated to 32×32, 16 cm). The region of 
interest is the outlined region in the right putamen. An elevated lactate doublet 
peak (the lactate peak is upward at this Te time) is found at the echo time of 135 
ms.  N-acetylaspartate  (NAA),  choline-containing  compounds  (Cho),  creatine  + 
phosphocreatine (Cr), and second creatine (Cr2) peaks are also shown.
Figure 2 Axial MRi scan (A) and MRS spectrum (B) of a 17-year old male with Leigh 
syndrome due to a mutation in the mtDNA.
Notes: (A) Axial fluid-attenuated inversion recovery image from a 3 T scanner 
(Siemens Trio) of a 17-year-old teenage boy with Leigh syndrome resulting from a 
mitochondrial DNA mutation (m.3700 G>A). There is a T2/fluid-attenuated inversion 
recovery hyperintensity in the caudal pons. Not shown is the hyperintensity that 
extends to the cervicomedullary junction. There were no abnormalities noted in the 
basal ganglia. (B) Summed spectrum from the caudal pons in the same patient using 
the point-resolved spectroscopy pulse sequence (3 T Siemens Trio; Te, 135 ms; 
TR, 5,180; 16×16 acquisition, interpolated to 32×32 cm). The region of interest is 
the outlined region of the caudal pons. An elevated lactate doublet peak is found 
at the echo time of 135 ms (peak is downward at this Te time). There is a reduced 
N-acetylaspartate (NAA) peak suggesting loss of neuronal integrity in the same 
region. Choline-containing compounds (Cho), creatine + phosphocreatine (Cr), and 
second creatine (Cr2) peaks are also shown.
B
0.4
0.3
0.2
0.1
0.0
−0.1
4 3 2 1
ppm
Cr2
Cho
NAA
Shift overlay from 60xx to 7 FE0
Cr
I : 0.517
I : 1.25
I : 1.83
I : 1.85
I : Integral
neuronal death, whereas the elevation of the lactate doublet 
peak is a sign of dysfunctional OXPHOS.
Individual causes of Leigh syndrome can demonstrate 
variable MRI findings. PDH deficiency typically has classic 
findings described in Leigh syndrome with T1 and T2 pro-
longation or hyperintensity of the corpus striatum (caudate 
and putamen) in addition to delayed myelination. MRS can 
show large lactate doublet and small N-acetylaspartate peaks 
in affected regions.66,67 Patients with COX deficiency with 
SURF1 mutations can have characteristic T1 and T2 prolon-
gations in the subthalamic nuclei, medulla, inferior cerebel-
lar peduncles, inferior olives, and nucleus of the solitary 
tract in the medulla and central tegmental tract and reticular 
formation in the dorsal pons and periaqueductal gray matter The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
230
Ruhoy and Saneto
of the mesencephalon.33–35 However, even within patients 
  having SURF1 mutations, there is variability in brain findings 
on MRI.33 Lactate peak is not seen on proton MRS in these 
patients, likely stemming from quiescence of the disease, at 
which time lactate is likely not present.6 Cerebral dysgenesis 
can be seen, especially in PDH deficiency, with E1 alpha sub-
unit deficiency. MILS arising from mutations of the ATPase 6 
gene (complex V) is less homogeneous than the SURF1 group. 
However, some cases do demonstrate involvement of the 
anterior putamen, dorsal mesencephalon, and dorsal pons.36,68 
The etiology of the heterogeneity of MRI findings within and 
between specific genetic etiologies is not clear.
Biochemical confirmation is most often seen in alterations 
of enzyme activity of one or a combination of the respira-
tory chain complexes. As described in further detail later, 
the respiratory chain is responsible for the synthesis of ATP. 
Muscle biopsy is the most common diagnostic tool for assay 
material.69 However, there are situations in which other tissue 
testing can be used for respiratory chain analysis, such as 
cultured fibroblasts.7,47 Other biochemical modalities such 
as blue native gel electrophoresis and ultrastructural analy-
sis of muscle can give clues to diagnosis, as can abnormal 
histochemical staining findings of COX deficiency, succinate 
dehydrogenase deficiency, and/or Gomori trichrome.7,47,70 
Structural changes in mitochondria may or may not be seen. 
Enzymology is not diagnostic in many instances of Leigh syn-
drome, but alterations in respiratory chain complex activity 
can be compromised by reductions in amounts resulting from 
nuclear-encoded assembly factor activity or other factors in 
respiratory chain function, such as decreased mitochondrial 
protein synthesis resulting from decreased formulation of 
Met-tRNA.7,14,36,47
At this time, diagnosis is based on the clinical scenario 
of a young child with developmental delay/regressions and, 
often, seizures. MRI findings often reveal bilateral, often 
symmetrical, necrotic lesions extending from the thalamus to 
the brainstem and the posterior columns of the spinal cord.5,6 
Lactate and pyruvate are less reliably elevated in the blood 
than they are in the cerebrospinal fluid. Cerebrospinal fluid 
values of lactate and pyruvate are important measurements 
for diagnosis. Elevated blood lactate levels are likely a result 
of respiratory chain dysfunction but are not highly specific.71 
If lactic acidosis is present because OXPHOS defects are 
present, corresponding elevations in plasma alanine are com-
monly seen. Renal tubular acidosis (Fanconi syndrome) may 
be present. Of note, significant elevated levels of ammonia, 
decreased blood glucose, and organic aciduria are usually 
not present.
As a result of the lack of a pathognomonic finding, a 
set of clinical, biochemical, and neuroimaging findings 
have been developed. Rahman et al12 established diagnostic 
criteria including progressive neurological disease with 
motor and intellectual developmental retardation/stagna-
tion, usually regression; signs and symptoms of brainstem 
and/or basal ganglia disease; raised lactate levels in blood 
and/or cerebrospinal fluid; and characteristic symmetric 
necrotic lesions in the basal ganglia and/or brainstem.12 As 
variability with biochemical findings may be dependent 
on disease activity, criteria for Leigh syndrome should be 
reflective of an overall clinical picture of degeneration, 
mitochondrial dysfunction, and neuroimaging findings.72 
Recently, Baertling et al offered a pathway for the diagnosis 
of Leigh syndrome.72 This pathway offers further diagnostic 
guidance with genetic testing and tissue histology in addi-
tion to the history, examination, laboratory values, and MRI 
findings within the diagnostic criteria of Rahman et al.12 It is 
important to note, however, that as genetic testing improves, 
the field is moving toward a genetic diagnosis being part of 
the criteria for Leigh syndrome, but we feel that until genetic 
testing becomes more sensitive and specific, it should not be 
included as a “required” criteria.
A remitting course with acute exacerbations is common. 
Episodes of decompensation, usually associated with ill-
nesses, result in developmental regression with an exacerba-
tion of symptoms such as abnormal tone and ataxia. In the 
majority of patients, the disease presents in the first year of 
life, most frequently before the age of 6 months, and death 
often occurs within 2 years of onset. Sofou et al proposed 
onset at 2 years of age as the cutoff for late-onset Leigh 
syndrome.5 Clearly, however, the diagnosis of Leigh syndrome 
in adults questions the validity of such a chronologic spec-
trum. It appears prognosis is, in part, related to the mutation 
identified and to heterogeneity of the phenotypic spectrum. 
SURF1-deficient Leigh syndrome was found to have a more 
favorable survival outcome compared with disease associated 
with complex I deficiency or LRPPRC mutations.33 Predictors 
of poorer prognosis include disease onset at age younger than 
6 months, failure to thrive, brainstem lesions of neuroimag-
ing, epileptic seizures that are difficult to treat, and history 
of intensive care hospitalization. However, all of the factors 
involved remain to be elucidated.
There is no specific treatment for Leigh syndrome, and 
generally specific therapy for mitochondrial disorders in 
child is not widely available. In spite of making considerable 
progress in our understanding of the molecular mechanisms 
underlying mitochondrial disease, the available therapeutic The Application of Clinical Genetics 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
231
Leigh syndrome: a genetically heterogeneous mitochondrial disorder
approaches are extremely limited but are still a very hot 
topic for current research goals. The aim of symptomatic 
treatment is to manage symptoms and to improve the 
energy state by increasing and optimizing ATP production 
and lowering lactate levels. This is accomplished by the 
elimination of noxious metabolics and the supply of oxygen 
radical scavengers. Antioxidants are a commonly employed 
mechanism in treatment, and there is currently no clear 
evidence in support of regular use of these drugs. EPI-743 
has been suggested to improve clinical outcomes in cases 
of genetically confirmed Leigh syndrome in one small and 
uncontrolled study.73 Of note, EPI-743 also arrested disease 
progression and reversed vision loss in all but one of the 
five consecutively treated patients with LHON.74 EPI-743 is 
an analogue of coenzyme Q10 and is thought to help increase 
intracellular glutathione, which is reduced in mitochondrial 
disorders.73 Encouraging studies suggest new medications 
might be helpful in Leigh syndrome, but well-controlled 
prospective studies are needed.
Supplementation with B vitamins, such as thiamine, 
which is a cofactor of PDH, has had no lasting effect, 
despite reports of neurological improvement with ribofla-
vin treatment.75,76 The beneficial effects of a ketogenic diet 
in a patient with PDHC deficiency have been reported.77 
Response to therapy has been monitored by a combination 
of MR imaging and MRS.
Symptomatic treatments including antiseizure medica-
tion to control seizures are an important part of treatment. 
Quality of life can improve significantly if seizures can be 
controlled without further adverse effects. Physiotherapy and 
pharmacotherapy for neuromuscular concerns, appropriate 
feeding methods to prevent malnutrition and aspiration, 
and aggressive treatment of fever and infections are further 
important treatment parameters to hopefully improve quality 
of life and decrease stress on both the patient and the family. 
Cardiology, pulmonology, and ophthalmology evaluations 
are important, as these organ manifestations would be impor-
tant to identify early on.
Considering the known genetic defects in the causation of 
mitochondrial disorders in general, and Leigh syndrome in 
particular, genetic-based therapeutic strategies are inarguably 
an important area of treatment available to patients. Although 
they are certainly in their infancy, there are several experi-
mental strategies currently under research and development. 
Examples include complementation through allotropic 
expression of protein and manipulation of heteroplasmy25 
by, for example, inhibiting the replication of mutant mtDNA 
through the sequence-specific binding of peptide nucleic 
acids. The long-term effectiveness of gene-based therapy 
has yet to be proven.
Conclusion
Leigh syndrome is a severe, progressive, multisystem, 
metabolic neurodegenerative disorder with distinct neuro-
radiological and neuropathological changes but prominent 
clinical and genetic heterogeneity. Leigh syndrome should 
be considered in all cases of early infantile progressive 
encephalopathy of unknown origin, especially when there 
is an associated nutritional disorder. There is currently 
limited knowledge regarding correlation phenotype and 
biochemical markers with the location of the mutant pro-
tein within the assembly, function, or structure of each 
complex of the mitochondrial respiratory chain. Indeed, 
this quest is complicated because a single family harbor-
ing the same mutation can have variable presentations and 
life expectancy. Although patients with mutations in core 
subunits have a significantly poorer prognosis than patients 
with mutations in noncore subunits, the variability in prog-
nosis is extremely high.7
With current genetic diagnostic technology, genetic 
mutations in both nuclear and mitochondrial genomes are 
identified at an increasing rate. Randomized controlled 
studies are still scarce. Successful treatments are even more 
elusive, and experimental therapeutic interventions should 
be aggressively considered and attempted.
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